Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab; Rituximab
- Indications CNS cancer; Eye neoplasms; Intraocular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 07 Aug 2020 Status changed from active, no longer recruiting to completed.
- 15 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Jan 2019.
- 15 Sep 2017 Status changed from recruiting to active, no longer recruiting.